EUCTR2015-001691-21-AT进行中（未招募）1 期
SAFETY, TOLERABILITY, rhBMP6 PHARMACOKINETICS AND BONE HEALING EFFECT OF A SINGLE DOSE OF OSTEOGROW (rhBMP6 IN AUTOLOGOUS WHOLE BLOOD COAGULUM DERIVED [WBCD] CARRIER) IN ADULT PATIENTS TREATED BY HIGH TIBIAL WEDGE OSTEOTOMY (HTO) FOR VARUS DEFORMITY OF THE KNEE
Genera Research Ltd0 个研究点目标入组 20 人开始时间: 2015年12月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients meeting ALL of the following criteria at screening will be eligible for participation in the study:
- •1.Willing and able to provide informed consent. A signed informed consent form must be provided before any study assessments are done. Patients must be fluent in the language that is spoken by the investigator and the trial staff and in which the informed consent is written.
- •2.Male or female, age =18 years. Females of childbearing potential must be using a highly effective method of birth control and must have a negative urine pregnancy test prior to the randomization.
- •3.Symptomatic varus deformity, assigned for unilateral high tibial opening wedge osteotomy (HTO).
- •4.Patients not receiving platelet aggregation inhibitors at least 5 days prior to surgery.
- •5.Patients should be otherwise healthy as defined by absence of clinically relevant abnormalities identified by a detailed medical history, full physical examination (including blood pressure and pulse rate measurement), 12-lead ECG, and clinical laboratory tests.
- •6.Willing and able to be confined to the hospital/inpatient unit for at least 5 days postoperatively and to comply with all other follow-up procedures according to the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients meeting ANY of the following criteria at screening will NOT be eligible for participation in the study:
- •1.Previous osteotomies of the tibia.
- •2.Inflammatory and neoplastic diseases of the knee joint.
- •3.Previous treatment with bone morphogenic proteins (e.g. Ossigraft)
- •4.Evidence or history of clinically significant hepatic disease (>3 x ULN for AST/ALT and total bilirubin) or other abnormalities in screening laboratory tests, which in the judgment of the investigator, would interfere with the patient’s participation in the study.
- •5.Presence or history of an uncontrolled, unstable, clinically significant medical condition (bone metabolic, renal, endocrine, hepatic, respiratory, cardiovascular, hematologic, immunologic or cerebrovascular disease, and malignancy) that in the judgment of the investigator may interfere with the interpretation of safety.
- •6.Other clinically significant systemic diseases.
- •7.History of symptomatic nephro- or urolithiasis within two years.
- •8.Diabetes mellitus.
- •9.Treatment with an investigational drug within 6 months or 5 half-lives (whichever is longer) preceding the first dose of study medication.
- •10.Screening 12-lead ECG demonstrating at least 1 of the following: Heart rate >100 bpm, QRS >120 msec, QTc > 430 msec (males), QTc >450 msec (females), or PR interval >220 msec.
- •11.Positive urine pregnancy test.
- •12.Breastfeeding a child or planning to become pregnant within 6 months.
- •13.Use within 7 days prior to surgery and postoperative for the duration of the study of the following medications: NSAIDs (paracetamol accepted) and systemic corticosteroids except for dexamethasone for the first 2 days postoperatively.
- •14.Known serological evidence of human immunodeficiency virus (HIV) antibody,
- •15.History of hepatitis B infection within the past year or history of non-adequately treated hepatitis C infection.
- •16.Patient is a known drug or alcohol abuser.
- •17.Donation of blood in excess of 500 mL within 56 days prior to and 1 month following surgery.
- •18. Current participation in any other clinical trial.
研究者
相似试验
招募中
不适用
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-111 and effect of food on the pharmacokinetics of ODM-111 and pharmacokinetic drug-drug interaction potential of ODM-111Chronic-/neuropathic pain10029305NL-OMON53911Orion Corporation182
进行中（未招募）
1 期
A study on the safety and effectiveness of the new investigational drug ODM-111 when given to healthy volunteers, and how ODM-111 is absorbed and processed by the human body.ovel treatment against chronic-/neuropathic pain.Nervous System DiseasesISRCTN84512888Orion Corporation (Finland)148
已完成
不适用
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of single and multiple escalating doses of ODM-108: a single centre study in healthy male volunteers.europathische pijn.Nerve damage pain.NL-OMON42514Orion Corporation Orion Pharma206
进行中（未招募）
1 期
A research study of how a new medicine NNC0365-3769 (Mim8) works in the body of healthy people and patients with bleeding disorderEUCTR2019-000465-20-ATovo Nordisk A/S94
进行中（未招募）
1 期
Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (Mim8) in healthy subjects and in subjects with haemophilia A with or without factor VIII inhibitors (NN7769-4513)severe haemophilia A with or without FVIII inhibitorsJPRN-jRCT2031200136Tsuchiyama Akio82